

**KDA GROUP BECOMES THE MAJORITY SHAREHOLDER OF CANNORTH MEDIC INC.,
A COMPANY IN THE CANNABIS FIELD FOR MEDICAL PURPOSES**

Thetford Mines, Quebec – July 3, 2018 – KDA Group Inc. (TSXV: KDA) (“**KDA Group**” or the “**Corporation**”) is proud to announce that it has signed an agreement for the acquisition of 51% of CanNorth Medic Inc.

“KDA Group is pursuing its mission to develop solutions and services for healthcare providers, and ultimately, to contribute to the well-being of the general public. This majority shareholder position will allow us to offer patients innovative cannabis-based medical products” explained Marc Lemieux, President and CEO of KDA Group.

THE POTENTIAL OF MEDICAL CANNABIS

“It has been established that 40%–60% of medications on the global market originate from plant extracts, including recent, highly effective chemotherapy agents such as taxanes. The use of cannabinoids, like all medications, must take place in well-researched and recognized fields such as oncology and chronic pain, among others. The undeniable potential for cannabinoids to replace other medications that have major side effects should foster the introduction of medical derivatives of cannabis in clinicians’ treatment arsenal, for the ultimate benefit of patients. Despite conclusive medical literature, the proven therapeutic benefits of cannabinoids continue to be greatly underestimated and underused among the general public and in the medical community.”

Dr. Éric Poirier, Surgical Oncologist practising at the Centre Hospitalier Universitaire de Québec

According to Dr. Poirier, it is unfortunate, even today, that pharmacological derivatives of cannabis sometimes receive negative press by being misleadingly associated with recreational use and its potential for abuse. Medical and recreational use of cannabis are two completely different issues.

For example, as reported by D.W. Bowles et al., the medical use of cannabis in oncology represents less than 3% of all prescriptions in the United States, compared with 8%–23% in the Netherlands.¹ The legalization of medical cannabis production in Canada will also lead to advanced scientific research to identify the most active therapeutic molecules and their best delivery methods. As with all approved medications, patients and healthcare workers are entitled to expect the best available quality and the uninterrupted availability of therapeutic products.

KDA GROUP’S CONTRIBUTION

KDA Group’s contribution in this strategic partnership is based on its pharmaceutical expertise throughout its various divisions.

The agreement is conditional on obtaining all required approvals, including final consent from the TSX Venture Exchange.

ABOUT KDA GROUP

KDA is a leading generic drug distributor and specialized solution provider in the pharmaceutical market. Today it is a respected name for quality and expertise among the different stakeholders in the pharmaceutical sector. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at www.groupekda.ca and on SEDAR at www.sedar.com.

REFERENCE

1- The Intersection between cannabis and cancer in the United States. D.W. Bowles et al, Critical Reviews in Oncology/Hematology 83 (2012) 1-10

- 30 -

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release from KDA group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this News Release.

INFORMATION

Marc Lemieux
Chief Executive Officer
514 622-7370
info@groupekda.ca